fbpx

Check out the latest episodes of our Life Science and Food Industry Podcasts. Available everywhere!

X

BioNTech Partners with Matinas BioPharma for mRNA Vaccine Delivery Tech + Pfizer Acquires ReViral for RSV Therapeutics – Xtalks Life Science Podcast Ep. 57

BioNTech Partners with Matinas BioPharma for mRNA Vaccine Delivery Tech + Pfizer Acquires ReViral for RSV Therapeutics – Xtalks Life Science Podcast Ep. 57

In this episode, Ayesha discussed BioNTech’s new collaboration with Matinas BioPharma to explore the company’s lipid nanocrystal (LNC) delivery technology for mRNA vaccines. LNC structures are more stable than the lipid nanoparticle technology used in the current COVID-19 mRNA vaccines. Learn about how BioNTech hopes to leverage Matinas’ LNC platform to develop improved mRNA vaccines, including the possibility of orally administered vaccine formulations.

The editorial team also talked about Pfizer’s acquisition of RSV antiviral therapeutics company ReViral Ltd. in a $525 million deal. Pfizer made the purchase to help expand its RSV portfolio, which currently includes a candidate RSV vaccine that received breakthrough therapy designation from the FDA for the prevention of RSV in individuals 60 years of age and older. Find out how Pfizer is looking to expand its infectious disease portfolio after the great success of its COVID-19 program.

Listen on Apple Podcasts

Read the full articles here:

BioNTech Partners with Matinas BioPharma to Develop New Delivery Technology for mRNA Vaccines

Pfizer to Acquire RSV Antiviral Developer ReViral in $525 Million Deal

The weekly podcast is available for streaming every Wednesday on SpotifyApple Music and wherever you stream your podcasts.

Subscribe to the Xtalks Life Science Podcast to never miss a new episode.